18903-18-9

Basic information

• Product Name: 5-Aminothiazole-4-carboxylic acid ethyl ester
• Synonyms: 5-Aminothiazole-4-carboxylic acid ethyl ester;Ethyl 5-aminothiazole-4-carboxylate;ethyl 5-aminothiazole-4-carboxylate hydrochloride;4-Thiazolecarboxylic acid, 5-aMino-, ethyl ester;Ethyl 5-aMino-1,3-thiazole-4-carboxylate
• CAS NO: 18903-18-9
• Molecular Formula: C₆H₈N₂O₂S
• Molecular Weight: 172.20492
• Mol File: 18903-18-9.mol
• Article Data: 15

Chemical Properties

• Melting Point: 163.5 °C
• Boiling Point: 300.666 °C at 760 mmHg
• Flash Point: 135.638 °C
• Appearance: /
• Density: 1.337 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.588
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 1.67±0.10(Predicted)
• CAS DataBase Reference: 5-Aminothiazole-4-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Aminothiazole-4-carboxylic acid ethyl ester(18903-18-9)
• EPA Substance Registry System: 5-Aminothiazole-4-carboxylic acid ethyl ester(18903-18-9)

Safety Data

• Hazardous Substances Data: 18903-18-9(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Tetrahedron, 41, p. 5989, 1985 DOI: 10.1016/S0040-4020(01)91439-5

InChI:InChI=1/C6H8N2O2S/c1-2-10-6(9)4-5(7)11-3-8-4/h3H,2,7H2,1H3

Upstream product

• 52868-64-1 5-amino-2-thioxo-2,3-dihydro-thiazole-4-carboxylic acid ethyl ester 
• 69316-68-3 Natrium-dithioformiat 
• 32683-02-6 ethyl-2-aminocyano acetate 
• 31785-10-1 2-formylamino-3-thio-malonamic acid ethyl ester 
• 3849-21-6 ethyl cyanoglyoxylate-2-oxime 
• 105-56-6 ethyl 2-cyanoacetate 
• 52868-64-1 ethyl 5-amino-2-mercaptothiazole-4-carboxylate 
• 1759-25-7 ethyl 2-cyano-2-(formyl-amino)acetate 
• 37842-62-9 ethyl N-(carbamoylcyanomethyl)formamidate 
• 19172-47-5 Lawessons reagent 

Downstream Products

• 114352-52-2 5-(4-aminophenylsulfonamido)thiazole-4-carboxylic acid 
• 852854-18-3 ethyl 5-(4-chlorophenylaminocarbonothioylamino)-1,3-thiazole-4-carboxylate 
• 911064-54-5 6-(4-fluorophenyl)-5-thioxo-5,6-dihydro[1,3]thiazolo[5,4-d]pyrimidin-7(4H)-one 
• 1572403-09-8 ethyl 5-((tert-butoxycarbonyl)amino)-2-(2,6-difluoro-4-methoxyphenyl)thiazole-4-carboxylate 
• 1394246-56-0 C₁₅H₁₆N₂O₂S 
• 1394246-62-8 C₁₃H₁₄N₂O₂S 
• 1228281-54-6 ethyl 5-amino-2-bromothiazole-4-carboxylate 
• 911064-54-5 6-(4-fluorophenyl)-5-mercapto[1,3]thiazolo[5,4]pyrimidin-7(6H)-one 
• 1028332-33-3 ethyl 5-(3-benzoylthioureido)thiazole-4-carboxylate 

Relevant articles and documents

REACTION OF ACYLAMINOCYANOESTERS WITH 2,4-BIS(4-METHOXYPHENYL)-1,3,2,4-DITHIADIPHOSPHETANE 2,4-DISULFIDE LEADING TO SUBSTITUTED AMINOTHIAZOLES. CRYSTAL STRUCTURE OF 5-AMINOTHIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER.

2-Acylamino-2-cyanoacetic acid ethyl esters 2a-c react with 2.4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane 2,4-disulfide 1 in refluxing benzene with formation of 2-alkyl(aryl)-5-aminothiazole-4-carboxylic acid ethyl esters 3a-c.Structure 3 was estab

Synthesis and biological evaluation of thiabendazole derivatives as anti-angiogenesis and vascular disrupting agents

Abstract Thiabendazole, already approved by FDA for oral use as an anti-fungal and anti-helminthic drug since 1967, has recently been repurposed as a vascular disrupting agent. By optimization of the structure of the lead compound, we successfully identified compound TBZ-19 and the new derivative is over 100-fold more potent than the lead compound against the growth of four different cell lines (A549, HCT-116, HepG2 and HUVECs). The most potent two candidates TBZ-07 and TBZ-19, exhibiting moderate inhibitory cell proliferation activity, were also verified as anti-angiogenesis and vascular disrupting agents. Therefore, TBZ-07 and TBZ-19 would be promising candidates with vasculature targeting activity and merit further development.

SUBSTITUTED ARYL PYRIMIDINONE DERIVATIVES

Substituted aryl pyrimidinone derivatives are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.